Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Clin Infect Dis
1 J Immunol
2 J Infect
18 J Infect Dis
1 J Pediatr
2 Lancet
3 MMWR Morb Mortal Wkly Rep
2 N Engl J Med
1 Nat Immunol
2 Nat Med
13 PLoS One
1 Science
13 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. CHAMBERS C, Samji H, Cooper CL, Costiniuk CT, et al
    COVID-19 Vaccine Effectiveness among a Population-based Cohort of People Living with HIV.
    AIDS. 2022 Oct 19. pii: 00002030-990000000-00126.
    PubMed         Abstract available


    Cholera: WHO rations vaccines to preserve stocks amid rising outbreaks.
    BMJ. 2022;379:o2528.

  3. What next for covid-19 vaccines?
    BMJ. 2022;379:o2535.

  4. LOOI MK, Mahase E
    What next for covid-19 vaccines?
    BMJ. 2022;379:o2422.

    Clin Infect Dis

  5. ASARE K, Andine T, Naicker N, Dorward J, et al
    Impact of point-of-care testing on the management of sexually transmitted infections in South Africa: Evidence from the HVTN702 HIV vaccine trial.
    Clin Infect Dis. 2022 Oct 15. pii: 6761890. doi: 10.1093.
    PubMed         Abstract available

    J Immunol

  6. LOBBY JL, Uddback I, Scharer CD, Mi T, et al
    Persistent Antigen Harbored by Alveolar Macrophages Enhances the Maintenance of Lung-Resident Memory CD8(+) T Cells.
    J Immunol. 2022;209:1778-1787.
    PubMed         Abstract available

    J Infect

  7. ZHENG Q, Wang M, Cheng Y, Liu J, et al
    Antibody response and safety of COVID-19 vaccine in peritoneal dialysis patients.
    J Infect. 2022 Oct 17. pii: S0163-4453(22)00612.

  8. NAZARETH J, Barr I, Sullivan SG, Goss C, et al
    Intra-season waning of immunity following the seasonal influenza vaccine in early and late vaccine recipients.
    J Infect. 2022 Oct 13. pii: S0163-4453(22)00604.

    J Infect Dis

  9. ZHOU F, Leung J, Marin M, Dooling KL, et al
    Health and Economic Impact of the United States Varicella Vaccination Program, 1996-2020.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  10. MORO PL, Leung J, Marquez P, Kim Y, et al
    Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  11. MARIN M, Seward JF, Gershon AA
    25 Years of Varicella Vaccination in the United States.
    J Infect Dis. 2022;226.

  12. SHAPIRO ED, Marin M
    The Effectiveness of Varicella Vaccine: 25 Years of Postlicensure Experience in the United States.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  13. ANDERSON M, Stec M, Gosha A, Mohammad T, et al
    Longitudinal SARS-CoV-2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid IgG.
    J Infect Dis. 2022 Oct 20. pii: 6764413. doi: 10.1093.
    PubMed         Abstract available

  14. LAAKE I, Skodvin SN, Blix K, Caspersen IH, et al
    Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the Omicron variant in a large, population-based, Norwegian cohort.
    J Infect Dis. 2022 Oct 19. pii: 6763324. doi: 10.1093.
    PubMed         Abstract available

  15. STUART A, Virta M, Williams K, Seppa I, et al
    Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV Seropositive Children 12-24 Months.
    J Infect Dis. 2022 Oct 19. pii: 6763323. doi: 10.1093.
    PubMed         Abstract available

  16. AGALLOU M, Koutsoni OS, Michail M, Zisimopoulou P, et al
    Antibody and T cell subsets analysis unveils an immune profile heterogeneity mediating long-term responses in individuals vaccinated against SARS-CoV-2.
    J Infect Dis. 2022 Oct 19. pii: 6763327. doi: 10.1093.
    PubMed         Abstract available

  17. BADIZADEGAN K, Kalkowska DA, Thompson KM
    Polio by the Numbers-A Global Perspective.
    J Infect Dis. 2022;226:1309-1318.
    PubMed         Abstract available

  18. ELAM-EVANS LD, Valier MR, Fredua B, Zell E, et al
    Celebrating 25 Years of Varicella Vaccination Coverage for Children and Adolescents in the United States: A Success Story.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  19. DREES M, Weber DJ
    Prevention and Control of Nosocomial Varicella During the United States Varicella Vaccination Program Era.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  20. DOLLARD S, Chen MH, Lindstrom S, Marin M, et al
    Diagnostic and Immunologic Testing for Varicella in the Era of High-Impact Varicella Vaccination: An Evolving Problem.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  21. LEUNG J, Lopez AS, Marin M
    Changing Epidemiology of Varicella Outbreaks in the United States During the Varicella Vaccination Program, 1995-2019.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  22. MARIN M, Lopez AS, Melgar M, Dooling K, et al
    Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  23. ARVIN AM
    Insights From Studies of the Genetics, Pathogenesis, and Immunogenicity of the Varicella Vaccine.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  24. WILLIS ED, Marko AM, Rasmussen SA, McGee M, et al
    Merck/Centers for Disease Control and Prevention Varicella Vaccine Pregnancy Registry: 19-Year Summary of Data From Inception Through Closure, 1995-2013.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  25. MARIN M, Leung J, Anderson TC, Lopez AS, et al
    Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  26. LEUNG J, Dooling K, Marin M, Anderson TC, et al
    The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

    J Pediatr

  27. DANINO D, Ashkenazi-Hoffnung L, Diaz A, Erps AD, et al
    Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for SARS-CoV-2 in Infants.
    J Pediatr. 2022 Oct 14. pii: S0022-3476(22)00896.
    PubMed         Abstract available


  28. THOMPSON MG, Yoon SK, Naleway AL, Meece J, et al
    Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers.
    JAMA. 2022;328:1523-1533.
    PubMed         Abstract available

    Rotavirus Leads Global Diarrhea Hospitalizations Among Young Children.
    JAMA. 2022;328:1490.

  30. RUBIN R
    The Dreaded "Twindemic" of Influenza and COVID-19 Has Not Yet Materialized-Might This Be the Year?
    JAMA. 2022 Sep 21. pii: 2796806. doi: 10.1001/jama.2022.15062.


  31. AGRAWAL U, Bedston S, McCowan C, Oke J, et al
    Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2022;400:1305-1320.
    PubMed         Abstract available

  32. MSELLATI P, Sow K, Desclaux A, Cottrell G, et al
    Reconsidering the COVID-19 vaccine strategy in West and Central Africa.
    Lancet. 2022;400:1304.

    MMWR Morb Mortal Wkly Rep

  33. SURIE D, Bonnell L, Adams K, Gaglani M, et al
    Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December
    MMWR Morb Mortal Wkly Rep. 2022;71:1327-1334.
    PubMed         Abstract available

  34. RAZZAGHI H, Srivastav A, de Perio MA, Laney AS, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - United States, 2021-22.
    MMWR Morb Mortal Wkly Rep. 2022;71:1319-1326.
    PubMed         Abstract available

  35. BRITTON A, Embi PJ, Levy ME, Gaglani M, et al
    Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1335-1342.
    PubMed         Abstract available

    N Engl J Med

  36. ANDERSON EJ, Creech CB, Berthaud V, Piramzadian A, et al
    Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
    N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMoa2209367.
    PubMed         Abstract available

  37. WITBERG G, Magen O, Hoss S, Talmor-Barkan Y, et al
    Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
    N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMc2207270.

    Nat Immunol

  38. QUAST I, Tarlinton D
    Time is of the essence for vaccine success.
    Nat Immunol. 2022 Oct 21. pii: 10.1038/s41590-022-01347.

    Nat Med

  39. ZAECK LM, Lamers MM, Verstrepen BE, Bestebroer TM, et al
    Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Nat Med. 2022 Oct 18. pii: 10.1038/s41591-022-02090.
    PubMed         Abstract available

  40. SCHEAFFER SM, Lee D, Whitener B, Ying B, et al
    Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Nat Med. 2022 Oct 20. pii: 10.1038/s41591-022-02092.
    PubMed         Abstract available

    PLoS One

  41. GAUTAM US, Asrican R, Sempowski GD
    Targeted dose delivery of Mycobacterium tuberculosis in mice using silicon antifoaming agent via aerosol exposure system.
    PLoS One. 2022;17:e0276130.
    PubMed         Abstract available

  42. VARGAS-HERRERA N, Fernandez-Navarro M, Cabezudo NE, Soto-Becerra P, et al
    Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
    PLoS One. 2022;17:e0268419.
    PubMed         Abstract available

  43. SEDEGAH M, Porter C, Goguet E, Ganeshan H, et al
    Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.
    PLoS One. 2022;17:e0276241.
    PubMed         Abstract available

  44. ALMANSOUR A, Hussein SM, Felemban SG, Mahamid AW, et al
    Acceptance and hesitancy of parents to vaccinate children against coronavirus disease 2019 in Saudi Arabia.
    PLoS One. 2022;17:e0276183.
    PubMed         Abstract available

  45. VANNI T, Thome BC, Sparrow E, Friede M, et al
    Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial.
    PLoS One. 2022;17:e0274943.
    PubMed         Abstract available

  46. NICKEL O, Rockstroh A, Wolf J, Landgraf S, et al
    Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    PLoS One. 2022;17:e0263861.
    PubMed         Abstract available

  47. DAHAL S, Pokhrel S, Mehta S, Karki S, et al
    Acceptance and hesitancy of COVID-19 vaccine among Nepalese population: A cross-sectional study.
    PLoS One. 2022;17:e0275922.
    PubMed         Abstract available

  48. AMIN MB, Roy N, Meem AE, Hossain E, et al
    Trends and determinants of taking tetanus toxoid vaccine among women during last pregnancy in Bangladesh: Country representative survey from 2006 to 2019.
    PLoS One. 2022;17:e0276417.
    PubMed         Abstract available

  49. NAKAMURA A, Kotaki T, Nagai Y, Takazawa S, et al
    Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon.
    PLoS One. 2022;17:e0274829.
    PubMed         Abstract available

  50. TADROUS M, Chung H, Men S, Chu C, et al
    Risk of SARS-CoV-2 infection following initial COVID-19 vaccination: Population-based cohort study.
    PLoS One. 2022;17:e0273903.
    PubMed         Abstract available

  51. PARKER SJ, DeLaroche AM, Hill AB, Arora R, et al
    Influenza vaccination coverage among an urban pediatric asthma population: Implications for population health.
    PLoS One. 2022;17:e0269415.
    PubMed         Abstract available

  52. MARTINELLI M, Veltri GA
    Shared understandings of vaccine hesitancy: How perceived risk and trust in vaccination frame individuals' vaccine acceptance.
    PLoS One. 2022;17:e0276519.
    PubMed         Abstract available

  53. ALMONGY HM, Almetwally EM, Haj Ahmad H, H Al-Nefaie A, et al
    Modeling of COVID-19 vaccination rate using odd Lomax inverted Nadarajah-Haghighi distribution.
    PLoS One. 2022;17:e0276181.
    PubMed         Abstract available


  54. VOGEL G
    New Omicron strains may portend big COVID-19 waves.
    Science. 2022;377:1479.
    PubMed         Abstract available


  55. GOLLAMUDI J, Sartain SE, Navaei AH, Aneja S, et al
    Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2022;40:6431-6444.
    PubMed         Abstract available

  56. RUAN J, Dong W, Liu Y, Zhang Y, et al
    Establishment of a model to assess mumps virus neurovirulence in neonatal Wistar rats.
    Vaccine. 2022;40:6397-6403.
    PubMed         Abstract available

  57. FUJI N, Pichichero M, Kaur R
    Pathogenesis of Streptococcus pneumoniae serotype 3 during natural colonization and infections among children and its IgG correlate of protection in a mouse model.
    Vaccine. 2022;40:6412-6421.
    PubMed         Abstract available

  58. MO Y, Li Y, Liu G, Chen J, et al
    A phase II, single-center, randomized, double-blind, parallel control clinical study evaluating the immunogenicity and safety of a two-dose schedule of serogroups ACYW meningococcal polysaccharide conjugate vaccine.
    Vaccine. 2022 Oct 12. pii: S0264-410X(22)00948.
    PubMed         Abstract available

  59. CHAO CR, Xu L, Cannizzaro N, Bronstein D, et al
    Trends in HPV vaccine administration and HPV vaccine coverage in children by race/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01195.
    PubMed         Abstract available

  60. SAADE EA, Abul Y, McConeghy K, Edward Davidson H, et al
    High-dose influenza vaccines for the prevention of hospitalization due to cardiovascular events in older adults in the nursing home: Post-hoc analysis of a cluster-randomized trial.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01215.
    PubMed         Abstract available

  61. AROCHO ROSARIO CM, Miller RJ, Klafke GM, Coates C, et al
    Interaction between anti-tick vaccine and a macrocyclic lactone improves acaricidal efficacy against Rhipicephalus (Boophilus) microplus (Canestrini) (Acari: Ixodidae) in experimentally infested cattle.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01230.
    PubMed         Abstract available

  62. CREISHER PS, Campbell AD, Perry JL, Roznik K, et al
    Influenza subtype-specific maternal antibodies protect offspring against infection but inhibit vaccine-induced immunity and protection in mice.
    Vaccine. 2022 Oct 14. pii: S0264-410X(22)01241.
    PubMed         Abstract available

  63. HUDSON A, Hall PA, Hitchman SC, Meng G, et al
    Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and unvaccinated general population members.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01242.
    PubMed         Abstract available

  64. TAKAHASHI Y, Ishitsuka K, Sampei M, Okawa S, et al
    COVID-19 vaccine literacy and vaccine hesitancy among pregnant women and mothers of young children in Japan.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01227.
    PubMed         Abstract available

  65. AKSOY N, Ozturk N, Ulusoy S, Omur MF, et al
    Knowledge and attitude of students studying at health department towards HPV and HPV vaccination.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01264.
    PubMed         Abstract available

  66. LIAO SH, Chang WJ, Hsu CY, Ming-Fang Yen A, et al
    Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01258.
    PubMed         Abstract available

  67. AMANI A, Ngo Bama S, Dia M, Nguefack Lekelem S, et al
    Challenges, best practices, and lessons learned from oral cholera mass vaccination campaign in urban Cameroon during the COVID-19 era.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)01004.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.